GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » Valuation Rank

Shandong Boan Biotechnology Co (HKSE:06955) Valuation Rank


View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Shandong Boan Biotechnology Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Boan Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Executives
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
China Cinda Asset Management Co., Ltd. 2201 Interest of corporation controlled by you
Li Li 2201 Interest of corporation controlled by you
Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si